Abstract

    Open Access Mini Review Article ID: GJCT-2-107

    Bortezomib in Anti-Cancer Activity: A Potential Drug

    Rajagopal Appavu* and Deepa Mohan

    26S proteasome is an intracellular; ATP dependent enzymatic complex degrades ubiquitin-tagged proteins and maintains cellular homeostasis. The orderly degraded proteins including cyclins, caspases, Bcl-xL, p53, cell adhesion molecules are involved in cell-cycle progression, tumor suppression, DNA replication, inflammation, and apoptosis. So, proteasome inhibition is a target therapy for cancer to promote cell cycle arrest or apoptosis. Bortezomib (Velcade®, PS-341, and Millennium Pharmaceuticals, Inc.) is the first, selective, reversible, and only proteasome inhibitor for the treatment of multiple myeloma have been approved by U.S. Food and Drug Administration (FDA) in 2003. Bortezomib downregulates the interaction of multiple myeloma cells with bone marrow stromal cells, inhibits angiogenesis, and blocks cell cycle progression. Clinically, continuous dosage of bortezomib leads to few side effects.

    Keywords:

    Published on: Mar 8, 2016 Pages: 5-8

    Full Text PDF Full Text HTML DOI: 10.17352/gjct.000007
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Case Reports

    Pinterest on GJCT